Post by Sanofi Belgium

We are thrilled to announce that Sanofi Belgium has been re-elected to the pharma.be General Assembly Board!   We're proud that Bart Vermeulen will continue representing Sanofi Belgium on the GM board. This re-election reflects our unwavering commitment to advancing healthcare innovation in Belgium and beyond.   Our shared priorities with pharma.be align perfectly with our mission to improve patient outcomes: 🚀 Fast and sustainable market access — ensuring that innovative treatments reach patients quickly and at a price that reflects their true value, with authorities treating healthcare as an investment, not a cost 🏭 Belgium as an attractive hub for R&D and manufacturing — reinforcing Belgium's position as a destination of choice for pharmaceutical investment, with clinical trials as a key building block 📋 Reducing administrative burden — improving the reimbursement framework and cutting unnecessary complexity that slows down access and discourages investment 🤝 Stakeholder dialogue and public-private partnerships — bringing industry, healthcare professionals, authorities, and patient organizations together as trusted partners, actively working toward shared solutions   We're honoured to continue this important work alongside our industry partners, driving innovation that makes a real difference in patients' lives. Together, we're not just shaping the future of healthcare - we're chasing the miracles of science.